Print page
Email page
Download PDF
« Previous Release | Next Release »
POINT RICHMOND, Calif., June 3, 2010 /PRNewswire via COMTEX News Network/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced Transcept management is scheduled to present a general business overview and product pipeline update at the Jefferies 2010 Global Life Sciences Conference in New York on Thursday, June 10th, at 8:30 a.m. Eastern Time.
A live audio webcast and replay of the presentation will be available at http://www.wsw.com/webcast/jeff46/tspt and on the Transcept Investor webpage at www.transcept.com.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo(R) (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo(R) NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo(R) in the United States. For further information, please visit the company's website at: www.transcept.com.
Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Director, Corporate Communications
(510) 215-3567
gmann@transcept.com
SOURCE Transcept Pharmaceuticals, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved